Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 04 2024
17 04 2024
Historique:
received:
16
01
2024
accepted:
05
04
2024
medline:
19
4
2024
pubmed:
18
4
2024
entrez:
17
4
2024
Statut:
epublish
Résumé
In this study, we aimed to establish a technique for intraprostatic implantation of prostate cancer (PCa) spheroids and to identify the impact of three-dimensional organization of PCa cells on tumor progression and metastasis in a representative in vivo model. 40,000 LNCaP cells were implanted into the prostate of immunodeficient SCID mice either as single cells (n = 8) or as preformed 3D spheroids (n = 8). For a follow up of 20 weeks, tumor growth was monitored by serum PSA and high-resolution 3D ultrasonography. Eventually, animals were sacrificed and autopsied. The organ dissects were analyzed for the presence of metastases by histology (H&E) and immunohistochemistry (AMACR, AR, Ki-67, CK5, CK8, E-Cadherin, Vimentin). Solid intraprostatic tumors developed in 50% of mice after spheroid implantation and in 50% of mice after implantation of a single cells. Primary tumors of LNCaP spheroids evolved earlier, exhibiting a shorter tumor doubling time whilst developing larger tumor volumes, which was reflected by a higher immunohistochemical expression of Ki-67 and AR, too. Spheroid tumors established lung and lymph node metastases in 75% of mice, in contrast to 50% of mice after single cell implantation. Our technique enables a variety of studies regarding the influence of the tumor microenvironment on PCa progression.
Identifiants
pubmed: 38632341
doi: 10.1038/s41598-024-59052-0
pii: 10.1038/s41598-024-59052-0
pmc: PMC11024136
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8835Informations de copyright
© 2024. The Author(s).
Références
Nat Rev Urol. 2023 Mar;20(3):158-178
pubmed: 36451039
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):179-92
pubmed: 11033305
Biotechnol J. 2008 Oct;3(9-10):1172-84
pubmed: 18566957
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Mol Cell Cardiol. 2011 Feb;50(2):290-5
pubmed: 21047516
Prostate. 1998 Apr 1;35(1):1-10
pubmed: 9537593
Cancer Res. 1983 Apr;43(4):1809-18
pubmed: 6831420
Cell Commun Signal. 2020 Jan 24;18(1):11
pubmed: 31980029
BJU Int. 2003 Jun;91(9):789-94
pubmed: 12780833
Am J Cancer Res. 2022 Mar 15;12(3):1116-1128
pubmed: 35411223
Prostate. 2015 Oct;75(14):1526-37
pubmed: 26074274
Clin Cancer Res. 1999 Oct;5(10 Suppl):3171s-3176s
pubmed: 10541360
Prostate. 2018 Jun;78(9):664-675
pubmed: 29572953
MAGMA. 2005 Dec;18(6):293-301
pubmed: 16328228
Immunotherapy. 2011 Nov;3(11):1367-84
pubmed: 22053887
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2021 Mar 4;11(1):5118
pubmed: 33664329
Nat Rev Urol. 2020 Jan;17(1):11-27
pubmed: 31827264
Nature. 2003 Aug 21;424(6951):870-2
pubmed: 12931155
Oncotarget. 2016 Mar 22;7(12):14639-58
pubmed: 26840259
Mol Carcinog. 2015 Jul;54(7):554-65
pubmed: 24347249
J Cancer Res Clin Oncol. 2019 Mar;145(3):551-559
pubmed: 30474758
Anticancer Res. 1998 Nov-Dec;18(6A):4147-58
pubmed: 9891460
Yakugaku Zasshi. 2008 Jan;128(1):37-44
pubmed: 18176054
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9
pubmed: 11531144
Oncogene. 2013 Sep 12;32(37):4343-54
pubmed: 23085755
Am J Pathol. 2012 Feb;180(2):473-83
pubmed: 22197383
Adv Drug Deliv Rev. 2014 Dec 15;79-80:214-21
pubmed: 24816064
Biomed Eng Online. 2016 Apr 27;15:46
pubmed: 27121383
Sci Rep. 2020 Jul 28;10(1):12575
pubmed: 32724081
Prostate. 2013 Sep;73(12):1251-62
pubmed: 23740600
Tumour Biol. 2016 Feb;37(2):2481-96
pubmed: 26385771
Tissue Eng. 2004 Jul-Aug;10(7-8):1266-76
pubmed: 15363181